Springer Nature
Browse
12936_2019_2909_MOESM2_ESM.png (96.51 kB)

MOESM2 of Efficacy and safety of dihydroartemisinin–piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial

Download (96.51 kB)
figure
posted on 2019-08-21, 04:29 authored by Esperança Sevene, Clifford Banda, Mavuto Mukaka, Sonia Maculuve, Salésio Macuacua, Anifa Vala, Mireia Piqueras, Linda Kalilani-Phiri, Jane Mallewa, Dianne Terlouw, Saye Khoo, David Lalloo, Victor Mwapasa
Additional file 2. Day 42 PCR-uncorrected efficacy plot. Kaplan–Meier survival plot of participants who were treated with dihydroartemisinin–piperaquine (DHA PPQ) in the efavirenz (EFV)- and nevirapine (NVP) based antiretroviral therapy (ART) groups according to polymerase chain reaction (PCR) uncorrected adequate clinical and parasitological response (ACPR) by day 42 in the intention-to-treat population with loss to follow up and indeterminate or unavailable PCR samples treated as treatment success.

Funding

European and Developing Countries Clinical Trials Partnership

History